시장보고서
상품코드
1147333

다형성교모세포종(GBM) 시장 : 시장 인사이트, 역학, 시장 예측(-2032년)

Glioblastoma Multiforme (GBM) Market Insight, Epidemiology and Market Forecast -2032

발행일: | 리서치사: DelveInsight Business Research LLP | 페이지 정보: 영문 326 Pages | 배송안내 : 1-2일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

주요 7개국의 다형성교모세포종(GBM) 시장 규모는 2021년에 7억 9,900만 달러로 평가되었습니다. 이 시장은 앞으로도 한층 더 확대될 것으로 예측됩니다.

주요 7개국의 다형성교모세포종(GBM: Glioblastoma Multiforme) 시장에 대해 조사했으며, 시장 개요와 함께 역학, 환자 동향, 새로운 치료법, 2032년까지 시장 규모 예측 및 의료 미충족 요구 등의 정보를 제공합니다.

목차

제1장 주요 인사이트

제2장 보고서 서론

제3장 다형성교모세포종 시장 개요

제4장 역학과 시장 예측 조사 방법

제5장 다형성교모세포종(GBM) 개요

제6장 주요 이벤트

제7장 SWOT 분석

제8장 질환의 배경과 개요 : 다형성교모세포종

  • 서론
  • 다형성교모세포종의 분류
  • 교아종 유형
  • 증상
  • 병태생리학
  • 다형성교모세포종의 유전
  • 분자 분류
  • 다형성교모세포종의 진단
  • 교아종 개요

제9장 치료

  • 수술
  • 화학요법
  • 방사선
  • 기타
  • 투약에 의한 증상 관리
  • 치료 알고리즘

제10장 다양한 조직의 가이드라인과 추천 사항

제11장 역학과 환자수

  • 주요 조사 결과
  • 주요 7개국의 GBM 환자수
  • 가정과 근거
  • 미국
  • EU 4개국 및 영국
  • 일본

제12장 환자 동향

제13장 다형성교모세포종의 중요 엔드포인트

제14장 출시 제품

제15장 신약

제16장 GBM : 주요 7개국 시장 분석

  • 주요 조사 결과
  • 시장 전망
  • 주요 시장 예측의 전제조건
  • 속성 분석
  • 주요 7개국의 GBM 전체 시장 규모
  • 미국 시장 규모
  • EU 4개국 및 영국 시장 규모
  • 일본 시장 규모

제17장 KOL(Key Opinion Leader)의 견해

제18장 미충족 요구

제19장 시장 접근과 상환

  • 미국
  • 유럽
  • 일본

제20장 부록

제21장 DelveInsight의 서비스 내용

제22장 면책사항

제23장 DelveInsight에 대해

LSH 22.11.11

DelveInsight's " Glioblastoma Multiforme Market - Market Insights, Epidemiology and Market Forecast- 2032" report delivers an in-depth understanding of the GBM, historical and forecasted epidemiology as well as the GBM market trends in the United States, the EU-4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

GBM market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM market size from 2019 to 2032. The report also covers current GBM treatment practice/algorithm, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

  • The United States
  • The EU-4 (Germany, France, Italy, and Spain), and the United Kingdom
  • Japan

Study Period: 2019-2032.

Glioblastoma Multiforme Disease Understanding and Treatment Algorithm

Glioblastoma Multiforme Overview

GBM is the most frequently occurring type of primary tumors of the central nervous system (CNS) mostly in adults, and its poor prognosis has not been significantly improved despite the fact that the innovative diagnostic strategies and new therapies have been developed. GBM is often located in a region of the forebrain known as the cerebrum, which controls some of the most advanced process such as speech and emotions. The exact underlying cause of GBM is unknown. Some cases may develop from existing, low-grade astrocytomas (malignant transformation) or they may occur without any evidence of a previous tumor (de novo).

GBM Diagnosis

The diagnosis of GBM includes neurological exams (this exam tests vision, hearing, speech, strength, sensation, balance, coordination, reflexes and the ability to think and remember), angiograms, magnetic resonance imaging (MRI) and computerized tomography (CT), surgical biopsy and others.

GBM Treatment

Treatment for GBM usually includes a combination of surgery, chemotherapy, radiation, stereotactic radiosurgery and Tumor treatment fields (TTF). Chemotherapy includes Carmustine (BCNU), Lomustine (CCNU), or Gleostine (Generic), Gliadel wafer (biodegradable discs infused with BCNU), Temozolomide (Temodar) Cisplatin, Carboplatin, Etoposide and Irinotecan. They may be given as a single agent or in combination i.e. PCV (Procarbazine, CCNU, and Vincristine), Carboplatin/ Etoposide. The drugs most commonly used to treat brain tumors are temozolomide (Temodar) and bevacizumab (Avastin).

Glioblastoma Multiforme Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Incident Population of GBM, Gender-specific Diagnosed Incidence of GBM, Type-specific Diagnosed Incidence of GBM, Age-specific Diagnosed Incidence of GBM, Diagnosed Incident Population based on Primary Site of GBM, and Diagnosed Incident Population based on Histologic Classification of GBM Tumor in the 7MM market covering the United States, EU-4 countries (Germany, France, Italy, and Spain), the United Kingdom and Japan from 2019 to 2032.

Key Findings

This section provides glimpse of the GBM epidemiology in the 7MM.

Country Wise- Glioblastoma Multiforme Epidemiology

  • The epidemiology segment also provides the GBM epidemiology data and findings across the United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom and Japan.
  • The Total Diagnosed Incident Population of GBM in the 7MM comprised of 32,546 cases in 2021 and are projected to increase during the forecast period.
  • The Gender-specific Diagnosed Incidence of GBM in the United States, in which maximum cases were recorded in male population i.e., 7,705 in 2021, as compared to female population.
  • Among the EU-4, the UK countries, Germany accounted for the highest number of GBM cases, followed by France, whereas Spain accounted for the lowest cases in 2021.
  • In Japan, the Type-specific Diagnosed Incidence of GBM in Japan was of two types in which maximum cases were recorded of Primary GBM/ IDH-wild Type 2,541 in 2021 and is anticipated to rise during the forecast period.

GBM Drug Chapters

Drug chapter segment of the GBM report encloses the detailed analysis of GBM marketed drugs and emerging (Phase-III and Phase II and Phase I/II) pipeline drugs. It also helps to understand the GBM clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed drugs

Avastin: Genentech

Avastin (Bevacizumab) is a recombinant humanized monoclonal IgG1 antibody, which acts as angiogenesis inhibitor by blocking its target, vascular endothelial growth factor (VEGF). Bevacizumab binds to the vascular endothelial growth factor (VEGF) with its receptor VEGFR-1 and VEGFR-2, which are present on the surface of endothelial cells. In December 2017, the US FDA granted full approval of bevacizumab (Avastin) for the treatment of adults with recurrent GBM that has progressed following prior therapy.

Temodar/Temodal: Merck

The active pharmaceutical ingredient in Temodar/Temodal, is an imidazotetrazine derivative of the alkylating agent dacarbazine. Temozolomide is used for the treatment of several brain cancer forms, e.g., as a second-line treatment for astrocytoma and as a first-line treatment for GBM. The therapeutic benefit of temozolomide is due to its ability to alkylate/methylate DNA. In July 2006, the Japan Ministry of Health, Labor and Welfare (MHLW) approved Temodal (R) (temozolomide) Capsules for the treatment of malignant glioma.

Note: Detailed Current therapies assessment will be provided in the full report of GBM.

Emerging Drugs

Ofranergene obadenovec (VB-111): VBL Therapeutics

Ofranergene obadenovec (VB-111) is a first-in-class, targeted anticancer gene-therapy agent that is being developed by VBL Therapeutics to treat a wide range of solid tumors such as GBM. It is a non-replicating adenovirus 5 (Ad-5, El-deleted) carrying a proapoptotic human Fas-chimera transgene that targets angiogenic blood vessels and leads to vascular disruption. The drug has been rewarded Orphan Drug Designation from both US FDA and EMA for the treatment of patients with GBM. In addition, it has also been granted Fast Track Designation by the US FDA for prolongation of survival in patients with rGBM. Currently, the drug has completed phase III stage of clinical development for the patients with rGBM. In November 2017, VBL Therapeutics signed an exclusive license agreement with NanoCarrier for the development, commercialization, and supply of ofranergene obadenovec (VB-111) in Japan.

Trans Sodium Crocetinate: Diffusion Pharmaceuticals

Trans Sodium Crocetinate (TSC), being investigated by Diffusion Pharmaceuticals, is a first-in-class small molecule that, by its novel proprietary mechanism, safely reoxygenates oxygen-deprived tissue. It can act alone or with other treatments and presents opportunities in unmet medical needs across several markets. It can be used to enhance the cancer-killing power of radiation and chemotherapy for treating patients with GBM.

Selinexor (KPT-330): Karyopharm Therapeutics

Selinexor (KPT-330) is a first-in-class, oral Selective Inhibitor of Nuclear Export/SINE compound in development by Karyopharm Therapeutics. It functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus, which subsequently reinitiates and amplifies their tumor suppressor function; this is supposed to lead to the selective induction of apoptosis in cancer cells, while largely sparing normal cells. The drug has been approved with a brand name Xpovio for patients in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody. The phase II (KING) study was terminated due to sponsor decision.

VBI-1901: VBI Vaccines

VBI-1901 is a cancer vaccine that VBI Vaccines has designed to treat GBM and medulloblastoma, which are two types of brain tumors. It is designed to kill GBM and medulloblastoma tumor cells infected with cytomegalovirus or CMV. While the immune system already targets cells infected by viruses, VBI-1901's goal is to boost their immune response such viruses. CMV inside tumor cells generate proteins called viral antigens that travel to the cells' surface. Currently, the vaccine is in phase I/II stage of clinical development for the patients with recurrent GBM and the company expects to initiate a randomized, controlled clinical study with registration potential in the fourth quarter of 2021. Recently, in June 2021, the company was granted Fast track designation by the FDA for VBI-1901 for the treatment of recurrent GBM.

ITI-1000 (pp65 DC Vaccine): Immunomic Therapeutics

Immunomic Therapeutics (ITI) is developing ITI-1000 (pp65 DC vaccine), which is a cancer cell vaccine consisting of autologous dendritic cells (DCs) loaded with mRNA encoding the human cytomegalovirus (CMV) matrix protein pp65 as a fusion protein with the short lysosome-associated membrane protein (shLAMP), with potential immunostimulatory and antineoplastic activities. ITI-1000 is currently being investigated in a phase II ATTAC-II trial for Glioblastoma Multiforme, Glioblastoma, Malignant Glioma, Astrocytoma, Grade IV, and GBM and is funded by the National Cancer Institute.

Note: Detailed emerging therapies assessment will be provided in the final report.

GBM Market Outlook

Glioblastoma treatment is quite challenging as some cells may respond well to certain therapies, while others may not be affected at all. Because of this, the treatment plan for glioblastoma may combine several approaches. The treatment often comprises a combination of several therapies, including surgery, chemotherapy, radiation, or stereotactic radiosurgery followed by the additional/adjuvant treatments, such as chemotherapy or radiation therapy, after surgery.

The first step in treating glioblastoma is a surgical procedure to make a diagnosis, to relieve pressure on the brain, and to remove as much tumor as possible safely. Glioblastoma surgery is performed to achieve a "maximum safe resection," or removing as much of the tumor as possible without causing lasting neurological damage.

It is interesting to note that the emerging market of GBM includes budding gene therapy, i.e., Ofranergene obadenovec (VB-111) by VBL Therapeutics, followed by four vaccine/immunotherapy candidates such as VBI-1901, AV-GBM-1 and ITI-1000 (pp65 DC Vaccine), Tasadenoturev (DNX-2401) by VBI Vaccines, Aivita Biomedical, Immunomic Therapeutics, and DNAtrix, respectively.

The GBM pipeline possessed multiple potential drugs in late- and mid-stage developments to be launched shortly. Key players involved in robust research and development include Paxalisib (GDC-0084): Kazia Therapeutics, LAM561: Laminar Pharmaceuticals, Tasa-denoturev (DNX-2401): DNAtrix and, others are some of the major players that are going to alter the market dynamics in the coming years.

Key Findings

This section includes a glimpse of the GBM 7MM market.

  • The total market size of GBM in the 7MM is USD 799 million in 2021 and is projected to grow during the forecast period (2022-2032).
  • According to the estimates, the highest market size of GBM is from the United States, in 2021.
  • Among the EU4 (Germany, France, Italy, Spain), and the UK, in which Germany has the maximum revenue share in 2021 while Spain has the lowest market share.
  • The market size of GBM in Japan is USD 58 million in 2021 which is expected to rise during the forecast period (2022-2032).

The United States Market Outlook

The total market size of GBM in the United States is expected to increase with a CAGR of 13.1% during the study period (2019-2032).

EU-4 (Germany, France, Italy, and Spain), and the UK Market Outlook

The total market size of GBM in EU-4, the UK is expected to increase with a CAGR of 13.5% during the study period (2019-2032).

Japan Market Outlook

The total market size of GBM in Japan is expected to increase with a CAGR of 10.4% during the study period (2019-2032).

Analyst Commentary

  • The market of GBM is currently using Temozolomide (Temodar) and Bevacizumab (Avastin) as approved therapies, but the market lacks an effective strategy to cure glioblastoma, which provides a lucrative opportunity to develop more treatment options.
  • Advancement in the understanding of molecular mechanisms and gene mutations are leading to more promising and tailored therapeutic approaches for GBM patients
  • Owing to the launch of Bevacizumab biosimilars, a reduction in cost burden can be witnessed
  • Despite a strong pipeline, most of the emerging therapies tend to fail in the high phase trials
  • There is a substantial market opportunity for vaccines and oncolytic virus therapies in GBM

GBM Drugs Uptake

This section focusses on the rate of uptake of the potential drugs expected to get launched in the market during the study period 2019-2032. The analysis covers GBM market uptake by drugs; patient uptake by therapies; and sales of each drug. For example- Kintara Therapeutics 'VAL-083' is a DNA-targeting agent, in three distinct biomarker-driven GMB patient populations. VAL-083 can cross the blood-brain barrier (BBB), has biological and tumor affecting activity against a range of cancers, including GBM and ovarian cancer. As per our analysis VAL-083, drug uptake in the US is expected to be medium-fast with peak share of 12%, years to peak would be 7 years in first line, whereas in second-line peak share is estimated to 5.5%.

GBM Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, Phase II and Phase I/II stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing and patent details for GBM emerging therapies.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in the domain through primary research to fill the data gaps and validate our secondary research. Some of the leaders like Chief Executive Officer, VBL Therapeutics, Chief executive officer, DNAtrix, Chief Medical Officer, VBI Vaccines, Chief Medical Officer, Kazia Therapeutics and others. Their opinion helps to understand and validate current and emerging therapies treatment patterns or GBM market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform competitive and market Intelligence analysis of the GBM market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

  • The report covers the descriptive overview of GBM, explaining its causes, signs and symptoms, pathogenesis and currently available therapies.
  • Comprehensive insight has been provided into the GBM epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for GBM are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of GBM market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM GBM market.

Report Highlights:

  • In the coming years, GBM market is set to change due emerging therapies in the pipeline, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence GBM R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • As per DelveInsight's analysis the subtypes- specific of GBM include type specific cases of Primary GBM/ IDH-wild Type and Secondary GBM/ IDH Mutant.
  • Expected Launch of potential therapies, Paxalisib (GDC-0084): Kazia Therapeutics, LAM561: Laminar Pharmaceuticals, Tasa-denoturev (DNX-2401): DNAtrix and others might change the landscape in treatment of GBM.

GBM Report Insights

  • Patient Population
  • Therapeutic Approaches
  • GBM Pipeline Analysis
  • GBM Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

GBM Report Key Strengths

  • Eleven Years Forecast
  • 7MM Coverage
  • GBM Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

GBM Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • SWOT
  • Attribute Analysis

Key Questions

Market Insights:

  • What was the GBM market share (%) distribution in 2019 and how it would look like in 2032?
  • What would be the GBM total market size as well as market size by therapies across the 7MM during the study period (2019-2032)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest GBM market size during the study period (2019-2032)?
  • At what CAGR, the GBM market is expected to grow at the 7MM level during the study period (2019-2032)?
  • What would be the GBM market outlook across the 7MM during the study period (2019-2032)?
  • What would be the GBM market growth till 2032 and what will be the resultant market size in the year 2032?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of GBM?
  • What is the historical GBM patient pool in the United States, the EU4 (Germany, France, Italy, and Spain), the UK and Japan?
  • What would be the forecasted patient pool of GBM at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to GBM?
  • Out of the above-mentioned countries, which country would have the highest incident population of GBM during the study period (2019-2032)?
  • At what CAGR the population is expected to grow across the 7MM during the study period (2019-2032)?

Current Treatment Scenario and Emerging Therapies:

  • What are the current options for the treatment of GBM? What are the current treatment guidelines for the treatment of GBM in the US and Europe?
  • How many companies are developing therapies for the treatment of GBM?
  • How many emerging therapies are in the mid-stage and late stage of development for the treatment of GBM?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the GBM therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for GBM and their status?
  • What are the key designations that have been granted for the emerging therapies for GBM?
  • What are the 7MM historical and forecasted market of GBM?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the GBM.
  • To understand the future market competition in the GBM market and Insightful review of the SWOT analysis of GBM.
  • Organize sales and marketing efforts by identifying the best opportunities for GBM in the US, the EU-4 (Germany, Spain, Italy, and France) the United Kingdom and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for GBM market.
  • To understand the future market competition in the GBM market.

Table of Contents

1. Key Insights

2. Report Introduction

3. Glioblastoma Multiforme Market Overview at a Glance

  • 3.1. Market Share (%) Distribution of GBM in 2019 by Countries
  • 3.2. Market Share (%) Distribution of GBM in 2032 by Countries

4. Epidemiology and Market Forecast Methodology

5. Executive Summary of Glioblastoma Multiforme (GBM)

6. Key Events

7. SWOT Analysis

8. Disease Background and Overview: Glioblastoma Multiforme

  • 8.1. Introduction
  • 8.2. Classification of Glioblastoma Multiforme
  • 8.3. Glioblastoma Types
    • 8.3.1. Astrocytomas
    • 8.3.2. Ependymomas
    • 8.3.3. Oligodendrogliomas
    • 8.3.4. Mixed gliomas
    • 8.3.5. Optic pathway gliomas
  • 8.4. Symptoms
  • 8.5. Pathophysiology
    • 8.5.1. Macroscopic and Histological Features of GBM
    • 8.5.2. Genetic and Molecular Pathogenesis
  • 8.6. Inheritance of Glioblastoma Multiforme
    • 8.6.1. Genetic Variations of Glioblastoma Multiforme
    • 8.6.2. Isocitrate dehydrogenase mutations
    • 8.6.3. O (6)-Methylguanine-DNA methyltransferase promoter methylation
    • 8.6.4. Telomerase reverse transcriptase promoter mutations
    • 8.6.5. Epidermal growth factor receptor aberrations
    • 8.6.6. PTEN alterations
    • 8.6.7. Other novel genetic aberrations
  • 8.7. Molecular Classification
    • 8.7.1. Specific Molecular Biomarkers
  • 8.8. Diagnosis of Glioblastoma Multiforme
    • 8.8.1. Neurological Exams
    • 8.8.2. Angiograms
    • 8.8.3. Magnetic resonance imaging (MRI) and computerized Tomography (CT)
    • 8.8.4. Perfusion MRI
    • 8.8.5. MR spectroscopy
    • 8.8.6. Histological Diagnosis
    • 8.8.7. Surgical Biopsy
  • 8.9. Glioblastoma in Nut Shell

9. Treatment

  • 9.1. Surgery
  • 9.2. Chemotherapy
  • 9.3. Radiation
  • 9.4. Others
    • 9.4.1. Targeted therapy
    • 9.4.2. Tumor treatment fields (TTF)
    • 9.4.1. Targeted therapy
    • 9.4.2. Tumor treatment fields (TTF)
    • 9.4.3. Immunotherapy
  • 9.5. Management of Symptoms with Medication
  • 9.6. Treatment Algorithm

10. Guidelines and Recommendations from Different Organizations

  • 10.1. The American Society of Clinical Oncology (ASCO) Endorsed American Society for Radiation Oncology (ASTRO) Guideline on Radiation Therapy for Glioblastoma
  • 10.2. Guidelines for the Management of Glioblastoma (National Comprehensive Cancer Network [NCCN], 2022)
  • 10.3. Guidelines for the Management of Newly Diagnosed Glioblastoma (National Institute for Health and Care Excellence [NICE], 2021)
  • 10.4. Guidelines for the Treatment of Adult Glioblastoma (Japanese Society of Neurological Surgery, 2019)
  • 10.5. Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions
    • 10.5.1. Medical Management and Supportive Care
    • 10.5.2. Standard Therapy
    • 10.5.3. Surgical Management
    • 10.5.4. Radiotherapy Considerations
    • 10.5.5. Recurrent Glioblastoma Scenario
  • 10.6. Clinical Recommendation for Glioblastoma (Associazione Italiana di Oncologia Medica [AIOM], 2021)
  • 10.7. SEOM (Medical Oncology Spanish Society) Clinical Guidelines for Diagnosis and Treatment of Glioblastoma

11. Epidemiology and Patient Population

  • 11.1. Key Findings
  • 11.2. Total Incident Cases of GBM in the 7MM
  • 11.3. Assumptions and Rationale
  • 11.4. United States
    • 11.4.1. Total Incident Cases of GBM in the United States
    • 11.4.2. Gender-specific Incidence Cases of GBM in the United States
    • 11.4.3. Type-specific Incidence Cases of GBM in the United States
    • 11.4.4. Age-specific Incidence Cases of GBM in the United States
    • 11.4.5. Incident Cases based on Primary Site of GBM in the United States
    • 11.4.6. Incident Cases based on Histologic Classification of GBM Tumor in the United States
  • 11.5. EU-4 and UK
    • 11.5.1. Total Incident Cases of GBM in the EU-4 and the UK
    • 11.5.2. Gender-specific Incidence Cases of GBM in the EU-4 and the UK
    • 11.5.3. Type-specific Incidence Cases of GBM in the EU-4 and the UK
    • 11.5.4. Age-specific Incidence Cases of GBM in the EU-4 and the UK
    • 11.5.5. Incident Cases Based on Primary Site of GBM in the EU-4 and the UK
    • 11.5.6. Incident Cases based on Histologic Classification of GBM Tumor in the EU-4 and the UK
  • 11.6. Japan
    • 11.6.1. Total Incident Cases of GBM in Japan
    • 11.6.2. Gender-specific Incidence Cases of GBM in Japan
    • 11.6.3. Type-specific Incidence Cases of GBM in Japan
    • 11.6.4. Age-specific Incidence Cases of GBM in Japan
    • 11.6.5. Incident Cases based on Primary Site of GBM in Japan
    • 11.6.6. Incident Cases based on Histologic Classification of GBM in Japan

12. Patient Journey

13. Key Endpoints in Glioblastoma Multiforme

14. Marketed Products

  • 14.1. Key Cross
  • 14.2. OPTUNE: Novocure Limited
    • 14.2.1. Product description
    • 14.2.2. Regulatory milestones
    • 14.2.3. Other developmental activities
    • 14.2.4. Current pipeline activity
    • 14.2.5. Safety and efficacy
    • 14.2.6. Product profile
  • 14.3. AVASTIN (bevacizumab): Genentech
    • 14.3.1. Product description
    • 14.3.2. Regulatory milestones
    • 14.3.3. Other developmental activities
    • 14.3.4. Safety and efficacy
    • 14.3.5. Product profile
  • 14.4. TEMODAR (temozolomide): Merck
    • 14.4.1. Product description
    • 14.4.2. Regulatory milestones
    • 14.4.3. Other development activities
    • 14.4.4. Current pipeline activity
    • 14.4.5. Safety and efficacy
    • 14.4.6. Product profile
  • 14.5. DELYTACT: Daiichi Sankyo
    • 14.5.1. Product description
    • 14.5.2. Regulatory milestones
    • 14.5.3. Other developmental activities
    • 14.5.4. Safety and Efficacy
    • 14.5.5. Product profile
  • 14.6. TAFINLAR + MEKINIST: Novartis
    • 14.6.1. Product Description
    • 14.6.2. Regulatory Milestones
    • 14.6.3. Other Developmental Activities
    • 14.6.4. Clinical Development
    • 14.6.5. Safety and Efficacy
    • 14.6.6. Product profile

15. Emerging Drugs

  • 15.1. Key Competitors
  • 15.2. Regorafenib: Bayer
    • 15.2.1. Product description
    • 15.2.2. Other developmental activities
    • 15.2.3. Clinical development
    • 15.2.4. Safety and Efficacy
  • 15.3. ONC201: Chimerix
    • 15.3.1. Product description
    • 15.3.2. Other developmental activities
    • 15.3.3. Clinical development
    • 15.3.4. Safety and efficacy
  • 15.4. AV-GBM-1: Aivita Biomedical
    • 15.4.1. Product description
    • 15.4.2. Clinical development
    • 15.4.3. Safety and efficacy
  • 15.5. Enzastaurin (DB-102): Denovo Biopharma
    • 15.5.1. Product description
    • 15.5.2. Other developmental activities
    • 15.5.3. Clinical development
    • 15.5.4. Safety and efficacy
  • 15.6. DCVax-L: Northwest Therapeutics
    • 15.6.1. Product description
    • 15.6.2. Other developmental activity
    • 15.6.3. Clinical development
    • 15.6.4. Safety and efficacy
  • 15.7. Ofranergene Obadenovec (VB-111): VBL Therapeutics
    • 15.7.1. Product Description
    • 15.7.2. Other Developmental Activities
    • 15.7.3. Clinical Development
    • 15.7.4. Safety and Efficacy
  • 15.8. LAM561 (2-OHOA): Laminar Pharmaceuticals
    • 15.8.1. Product description
    • 15.8.2. Other developmental activities
    • 15.8.3. Clinical development
    • 15.8.4. Safety and Efficacy
  • 15.9 .MEDI4736 (durvalumab): MedImmune
    • 15.9.1. Product description
    • 15.9.2. Clinical Development
    • 15.9.3. Safety and Efficacy
  • 15.10. Tasadenoturev (DNX-2401): DNAtrix
    • 15.10.1. Product description
    • 15.10.2. Other developmental activities
    • 15.10.3. Clinical development
    • 15.10.4. Safety and Efficacy
  • 15.11. ITI-1000 (pp65 DC Vaccine): Immunomic Therapeutics
    • 15.11.1. Product description
    • 15.11.2. Other developmental activities
    • 15.11.3. Clinical development
    • 15.11.4. Safety and Efficacy
  • 15.12. IGV-001: Imvax
    • 15.12.1. Product description
    • 15.12.2. Other developmental activities
    • 15.12.3. Clinical development
    • 15.12.4. Safety and Efficacy
  • 15.13. SurVaxM: MimiVax
    • 15.13.1. Product description
    • 15.13.2. Other developmental activities
    • 15.13.3. Clinical development
    • 15.13.4. Safety and Efficacy
  • 15.14. Berubicin: CNS Pharmaceuticals
    • 15.14.1. Product description
    • 15.14.2. Other developmental activities
    • 15.14.3. Clinical development
    • 15.14.4. Safety and Efficacy
  • 15.15. GLIOVAC (Sitoiganap): Epitopoietic Research Corporation (ERC)
    • 15.15.1. Product description
    • 15.15.2. Other developmental activities
    • 15.15.3. Clinical development
    • 15.15.4. Safety and Efficacy
  • 15.16. Lerapolturev + Pembrolizumab: Istari Oncology
    • 15.16.1. Product description
    • 15.16.2. Other developmental activities
    • 15.16.3. Clinical development
    • 15.16.4. Safety and Efficacy
  • 15.17. SONALA-001 + Exablate 2.0 Device: SonALAsense
    • 15.17.1. Product description
    • 15.17.2. Clinical development
    • 15.17.3. Safety and Efficacy
  • 15.18. VAL-083 (dianhydrogalactitol): Kintara Therapeutics
    • 15.18.1. Product description
    • 15.18.2. Other developmental activities
    • 15.18.3. Clinical development
    • 15.18.4. Safety and efficacy
  • 15.19. Pomalidomide: Bristol Myers Squibb
    • 15.19.1. Product description
    • 15.19.2. Other Developmental Activities
    • 15.19.3. Clinical Development
    • 15.19.4. Safety and Efficacy
  • 15.20. MDNA55: Medicenna Therapeutics
    • 15.21.1. Product description
    • 15.21.2. Other developmental activities
    • 15.21.3. Clinical development
    • 15.21.4. Safety and efficacy
  • 15.21. BMX-001: BioMimetix
    • 15.21.1. Product description
    • 15.21.2. Other developmental activity
    • 15.21.3. Clinical development
    • 15.21.4. Safety and efficacy
  • 15.22. Lenvatinib ± Pembrolizumab: Eisai and Merck Sharp & Dohme
    • 15.22.1. Product description
    • 15.22.2. Clinical development
    • 15.22.3. Safety and efficacy
  • 15.23. Paxalisib (GDC-0084): Kazia Therapeutics
    • 15.23.1. Product description
    • 15.23.2. Other developmental activities
    • 15.23.3. Clinical development
    • 15.23.4. Safety and efficacy
  • 15.24. OKN-007: Oblato
    • 15.24.1. Product description
    • 15.24.2. Other developmental Activity
    • 15.24.3. Clinical development
    • 15.24.4. Safety and efficacy
  • 15.25. Temferon: Genenta Science
    • 15.25.1. Product description
    • 15.25.2. Clinical development
    • 15.25.3. Safety and Efficacy
  • 15.26. EO2401: Enterome
    • 15.26.1. Product description
    • 15.26.2. Clinical development
    • 15.26.3. Safety and Efficacy
  • 15.27. INO-5401+ INO-9012+ LIBTAYO (cemiplimab): Inovio Pharmaceuticals
    • 15.27.1. Product description
    • 15.27.2. Clinical development
    • 15.27.3. Safety and Efficacy
  • 15.28. Selinexor (KPT-330): Karyopharm Therapeutics
    • 15.28.1. Product description
    • 15.28.2. Clinical development
    • 15.28.3. Safety and efficacy
  • 15.29. Olutasidenib (FT-2102): Forma Therapeutics
    • 15.29.1. Product description
    • 15.29.2. Other developmental activities
    • 15.29.3. Clinical development
    • 15.29.4. Safety and efficacy
  • 15.30. VBI-1901: VBI Vaccines
    • 15.30.1. Product description
    • 15.30.2. Other developmental activities
    • 15.30.3. Clinical development
    • 15.30.4. Safety and efficacy
  • 15.31. NOX-A12/olaptesed pegol: TME Pharma
    • 15.31.1. Product description
    • 15.32.2. Other developmental activities
    • 15.33.3. Clinical development
    • 15.34.4. Safety and Efficacy

16. GBM: Seven Major Market Analysis

  • 16.1. Key Findings
  • 16.2. Market Outlook
  • 16.3. Key Market Forecast Assumptions
  • 16.4. Attribute Analysis
  • 16.5. Total Market Size of GBM in the 7MM
  • 16.6. United States Market Size
    • 16.6.1. Total Market size of GBM in the United States
    • 16.6.2. Market Size of GBM by Current and Emerging Therapies in the United States
  • 16.7. EU-4 and UK Market Size
    • 16.7.1. Total Market size of GBM in the EU-4 and the UK
    • 16.7.2. Market Size of GBM by Current and Emerging Therapies in the EU-4 and the UK
  • 16.8. Japan Market Size
    • 16.8.1. Total Market size of GBM in Japan
    • 16.8.2. Market Size of GBM by Current and Emerging Therapies in Japan

17. KOL Views

18. Unmet Needs

19. Market Access and Reimbursement

  • 19.1. United States
  • 19.2. Europe
  • 19.3. Japan

20. Appendix

  • 20.1. Bibliography
  • 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제